Supplementary Table S1. Characteristics of patients enrolled to PancSeq protocol

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic | Pilot Study  (N=10) | CLIA-Certified Study  (N=69) | Full Population  (N=79) |
| Age, median (range), years | 70 (62-85) | 63 (37-86) | 64 (37-86) |
| Female sex, N (%) | 3 (30) | 30 (43) | 33 (42) |
| Race/Ethnicity, N (%) |  |  |  |
| White | 8 (80) | 66 (96) | 74 (94) |
| Black | 1 (10) | 2 (3) | 3 (4) |
| Other/Unknown | 1 (10) | 1 (1) | 2 (3) |
| Histology, N (%) |  |  |  |
| Pancreatic adenocarcinoma | 9 (90) | 66 (96) | 75 (95) |
| Acinar cell carcinoma | 1 (10) | 0 (0) | 1 (1) |
| Undifferentiated carcinoma with  osteoclast-like giant cells | 0 (0) | 2 (3) | 2 (3) |
| Ampullary adenocarcinoma | 0 (0) | 1 (1) | 1 (1) |
| Stage of disease at biopsy, N (%) |  |  |  |
| Locally advanced | 1 (10) | 2 (3) | 3 (4) |
| Metastatic | 9 (90) | 67 (97) | 76 (96) |
| Prior treatment for advanced disease, N (%) |  |  |  |
| No prior chemotherapy | 9 (90) | 46 (67) | 55 (70) |
| One prior line of therapy | 0 (0) | 8 (12) | 8 (10) |
| Two or more prior lines of therapy | 1 (10) | 15 (22) | 16 (20) |
| Prior pancreatectomy, N (%) | 2 (20) | 14 (20) | 16 (20) |